AMGN Earnings Prediction
The chart below shows how AMGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AMGN sees a +1.38% change in stock price 10 days leading up to the earnings, and a +2.56% change 10 days following the report. On the earnings day itself, the stock moves by -0.38%. This data can give you a slight idea of what to expect for the next quarter's release.
AMGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
8.50B
23.18%
1.37%
Gross Margin
61.07%
-17.31%
-0.57%
Operating Margin
24.07%
-19.04%
5.76%
Net Margin
33.28%
32.80%
274.35%
EPS
5.22
62.11%
278.26%
No Data Available
AMGN Earnings Analysis
Amgen Inc Corporation (AMGN.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: In the third quarter, we delivered $8.5 billion in total revenues, a 23% year-over-year increase.
Sales Volume Surge: Product sales increased 8% year-over-year, driven by 12% volume growth.
Free Cash Flow Increase: In the third quarter, we generated $3.3 billion of free cash flow, an increase of $2.5 billion from the previous year.
Long-Term Growth Outlook: We have a strong long-term growth outlook with breadth and depth across each of our four therapeutic areas, including our innovative pipeline and in-market products, serving patients with serious illnesses around the globe.
2024 Revenue and EPS Guidance: We expect our 2024 total revenues in the range of $33.0 billion to $33.8 billion and non-GAAP EPS between $19.20 to $20.
Negative
Revenue Increase Analysis: Total revenues increased by 23% year-over-year to $8.5 billion, but excluding the addition of Horizon, product sales increased only by 8%.
Operating Expenses Surge: Operating expenses increased by 27% year-over-year, largely driven by the addition of Horizon, impacting overall profitability.
Operating Expenses Increase: Non-GAAP operating expenses rose significantly, with a reported $554 million expense, up $329 million year-over-year, primarily due to increased interest expenses from the Horizon acquisition.
Q4 EPS Outlook Decline: The company expects Q4 non-GAAP EPS to be lower than Q3 due to planned investment increases, indicating potential pressure on profitability in the near term.
Non-GAAP Tax Rate Decline: The non-GAAP tax rate decreased by 2.7 percentage points year-over-year to 13.4%, reflecting changes in earnings mix from the inclusion of Horizon, which may affect future tax liabilities.
AMGN FAQs
How does AMGN typically perform around its earnings report dates?
Is Amgen Inc. (AMGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AMGN Earning Call Sentiment
Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AMGN.O
2.73%Positive
Amgen's earnings call highlighted a robust financial performance with a 23% revenue increase and a strong pipeline with significant milestones anticipated in 2024. The Q&A session revealed optimism about MariTide's potential and biosimilars' market positioning, despite some management vagueness. The guidance is strong, with increased dividends and strategic R&D investments. Overall, the combination of solid financials, promising future developments, and shareholder returns suggests a positive stock price movement in the coming weeks.